UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000018754
Receipt number R000021695
Scientific Title Dapagliflozin effectiveness on the vascular endothelial function and glycemic control in T2D with moderately inadequate glycemic control
Date of disclosure of the study information 2015/08/21
Last modified on 2018/11/22 11:22:33

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Dapagliflozin effectiveness on the vascular endothelial function and glycemic control in T2D with moderately inadequate glycemic control

Acronym

Dapagliflozin effectiveness on the vascular endothelial function and glycemic control (DEFENCE study)

Scientific Title

Dapagliflozin effectiveness on the vascular endothelial function and glycemic control in T2D with moderately inadequate glycemic control

Scientific Title:Acronym

Dapagliflozin effectiveness on the vascular endothelial function and glycemic control (DEFENCE study)

Region

Japan


Condition

Condition

Type 2 diabetes

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study attempts to reveal the positive effects of dapagliflozin on body weight, blood pressure, lipid metabolism, glycemic levels and endothelial function in Japanese T2D patients with moderately inadequate glycemic control including elderly, by using FMD and CAVI values to compare with metformin.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Change in FMD volume from baseline to the 16-week observation point

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -but assessor(s) are blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Dapagliflozin as add-on medication group:
Patients enrolled in this group orally take dapagliflozin 5mg once per day in addition to other medications during the 16-week period.

Interventions/Control_2

Increase metformin dosage group:
Patients enrolled in this group change their metformin dose from 750mg up to 1500mg, and orally take it in 2 or 3 times per day during the 16-week period.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >

Gender

Male and Female

Key inclusion criteria

Patients who meet all of the following criteria are included in this study.
1. In addition to a diet and exercise, type 2 diabetes patients who have been treating diabetes a) for more than 12 weeks using 750mg of metformin, or b) with one type of oral hypoglycemic agents* in addition to 750mg of metformin
*In the case of SU users, glimepiride (2 mg or less than it) or glimicron (40 mg or less than it) are allowed
2. HbA1c (NGSP values) 6.0% or higher and under 8.0%
3. Males or females aged 20 to 74
4. Patients who can closely follow the medication compliance
5. Patients who can provided written consent to participate in the clinical study

Key exclusion criteria

Patients who fall into any of the following criteria are excluded from participating in the study.
1. Type 1 diabetes or secondary diabetes
2. Had used SGLT2 inhibitors, GLP-1 agonists, or insulin 12 weeks before providing their consent
3. Had used a dose of metformin exceeding 750mg per day 12 weeks before providing their consent
4. Had started taking angiotensin-converting enzyme inhibitor (ACE inhibitor), angiotensin II receptor antagonist (ARB), HMG-CoA reductase inhibitor (statin), or antiplatelet drugs, or had their medication dose changed (including reducing the dose) 12 weeks before providing their consent
5. Patients who have a severe infection, have had or are about to have surgery, or are suffering from a serious trauma
6. With a medical history of myocardial infarction, angina, stroke or cerebral infarction
7. With atrial (chronic) fibrillation, frequent supraventricular or ventricular ectopy
8. With a moderate or severe level of cardiac insufficiency (patients with class III or more as classified by the NYHA/New York Heart Association)
9. Ankle Brachial Pressure Index (ABI)< 0.9
10. Serious liver or renal functional failure (serum creatinine 1.3mg/dL or greater, or eGFR< 45mL/min/1.73 square meters)
11. Unstable blood pressure or lipid abnormalities within 12 weeks before providing their consent
12. Addicted to alcohol or drugs
13. Patients who are pregnant or breastfeeding, or who may be, or plan to be, pregnant
14. Dehydrated (abnormal test results of hematocrit and BUN values, and complaint of symptoms of dehydration)
15. Using diuretics
16. Urinary tract or genital infections within 12 weeks before providing their consent
17. With a past history of hypersensitivity to the study drug
18. At risks of ketoacidosis, diabetic coma or precoma
19. Other conditions considered to be unsuitable by the attending physician

Target sample size

80


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Prof. Takahisa Hirose

Organization

Toho University Omori Medical Center

Division name

Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine

Zip code


Address

6-11-1 Omori Nishi, Ota-ku, Tokyo

TEL

03-3762-4151

Email

takahisa.hirose@med.toho-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Hiroki Takayama

Organization

Soiken Inc.

Division name

Clinical Study Support Division

Zip code


Address

NBF Ogawamachi Building 4F, Kanda Ogawamachi 1-3-1, Chiyoda-ku, Tokyo 101-0052

TEL

03-3295-1350

Homepage URL


Email

takayama@soiken.com


Sponsor or person

Institute

Japan Society for Patient Report Outcome

Institute

Department

Personal name



Funding Source

Organization

AstraZeneca K.K.
Ono Pharmaceutical Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 08 Month 21 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2015 Year 08 Month 14 Day

Date of IRB


Anticipated trial start date

2015 Year 10 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2015 Year 08 Month 21 Day

Last modified on

2018 Year 11 Month 22 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021695


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name